Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Non-Current Debt (2021)

Historic Non-Current Debt for ARS Pharmaceuticals (SPRY) over the last 1 years, with Q4 2021 value amounting to $4.9 million.

  • ARS Pharmaceuticals' Non-Current Debt changed N/A to $4.9 million in Q4 2021 from the same period last year, while for Dec 2021 it was $4.9 million, marking a year-over-year change of. This contributed to the annual value of $4.9 million for FY2021, which is N/A changed from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Non-Current Debt of $4.9 million as of Q4 2021.
  • ARS Pharmaceuticals' Non-Current Debt's 5-year high stood at $4.9 million during Q4 2021, with a 5-year trough of $4.9 million in Q4 2021.